Featured Research

from universities, journals, and other organizations

Rapid eye movements significantly delayed in people with glaucoma

Date:
December 6, 2012
Source:
St. Michael's Hospital
Summary:
Rapid eye movements are significantly delayed in patients with glaucoma, even those in the early stages of the disease, research has found.

Rapid eye movements are significantly delayed in patients with glaucoma, even those in the early stages of the disease, research has found.

The findings, led by Dr. Neeru Gupta, an ophthalmologist at St. Michael's Hospital, may shed new light on why glaucoma patients are at increased risk for falls and car accidents. Glaucoma is the leading cause of irreversible blindness.

Rapid (or saccadic) eye movements are the quick, simultaneous movements of both eyes in the same direction. They are involved in a myriad of everyday activities, from reading to scanning the surrounding environment, be it a busy subway station, grocery store shelves or oncoming traffic.

Dr. Gupta and co-workers studied groups of people with and without glaucoma who wore a head-mounted device that measured the length of time it took their eyes to move from one point to another, how long it took their eyes to begin the movement, did they focus on an object right away or did their eyes overshoot the target.

"Most of us take that processing of information for granted," she said.

However, she found that people with glaucoma showed delayed eye movement reaction times by about 15 per cent, even if they were in the early stages of the disease.

The findings were published online in the journal Eye and Brain.

Dr. Gupta said the findings are significant because they suggest that approaches to measuring vision loss beyond eye charts or visual field tests that related to real world settings may provide important clues to how the disease affects the lives of glaucoma patients. Glaucoma is becoming more common as the population ages and is expected to affect 80 million people worldwide by 2020. About half of all cases remain undiagnosed.

Currently, glaucoma can be diagnosed only by using a light to examine the optic nerve. Eye charts will not catch glaucoma, because it begins with peripheral vision loss long before reaching central vision.

All treatments for glaucoma -eye drops, laser surgery and conventional surgery -- are designed to reduce pressure in the eye and help slow or stabilize damage to optic nerve. No treatment can reverse the disease.

"Now that we know that eye movement reaction times are delayed in people with glaucoma, there is an opportunity to understand the effects of glaucoma on daily activities of living that most of us take for granted, such as walking up and down stairs, driving, navigating and reading. Dr. Gupta said. "Just as alcohol causes a delay in hitting the brakes, glaucoma slows the time it takes to move the eyes quickly in response to a visual cue."

In previous work, Dr. Gupta and colleagues have demonstrated that glaucoma is a neurodegenerative disease affecting major vision pathways in the brain. Dr. Gupta's current paper points to a new vision pathway in the brain that is affected in glaucoma. Ninety per cent of signals from the optic nerve travel to an area at the back of the brain called the lateral geniculate nucleus. But the brain signals for rapid eye movements appear to travel a different route through the area known as the superior colliculus. A previous smaller study by Lamirel and coworkers published in the Journal of Glaucoma in 2012 also showed that saccades were impaired in four glaucoma patients with visual field loss.

This research was funded by the Glaucoma Research Society of Canada, Dorothy Pitts Research Fund.


Story Source:

The above story is based on materials provided by St. Michael's Hospital. The original article was written by Leslie Shepherd. Note: Materials may be edited for content and length.


Journal Reference:

  1. Neeru Gupta, Kanjee, yeni Yucel, Steinbach, Gonzalez. Delayed saccadic eye movements in glaucoma. Eye and Brain, 2012; 63 DOI: 10.2147/EB.S38467

Cite This Page:

St. Michael's Hospital. "Rapid eye movements significantly delayed in people with glaucoma." ScienceDaily. ScienceDaily, 6 December 2012. <www.sciencedaily.com/releases/2012/12/121206122336.htm>.
St. Michael's Hospital. (2012, December 6). Rapid eye movements significantly delayed in people with glaucoma. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/12/121206122336.htm
St. Michael's Hospital. "Rapid eye movements significantly delayed in people with glaucoma." ScienceDaily. www.sciencedaily.com/releases/2012/12/121206122336.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins